Advancements and Challenges in Immune Protection Strategies for Islet Transplantation
Xue Wang,
Ziyuan Zeng,
Dayan Li,
Kai Wang,
Wei Zhang,
Yang Yu,
Xi Wang,
Xue Wang
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Search for more papers by this authorZiyuan Zeng
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Search for more papers by this authorDayan Li
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China
Search for more papers by this authorKai Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Wei Zhang
TianXinFu (Beijing) Medical Appliance co. Ltd., Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorCorresponding Author
Yang Yu
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorCorresponding Author
Xi Wang
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Institute of Advanced Clinical Medicine, Peking University, Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorXue Wang,
Ziyuan Zeng,
Dayan Li,
Kai Wang,
Wei Zhang,
Yang Yu,
Xi Wang,
Xue Wang
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Search for more papers by this authorZiyuan Zeng
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Search for more papers by this authorDayan Li
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China
Search for more papers by this authorKai Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Wei Zhang
TianXinFu (Beijing) Medical Appliance co. Ltd., Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorCorresponding Author
Yang Yu
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorCorresponding Author
Xi Wang
State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
Institute of Advanced Clinical Medicine, Peking University, Beijing, China
Correspondence:
Wei Zhang ([email protected])
Yang Yu ([email protected])
Xi Wang ([email protected])
Search for more papers by this authorFunding: This work was supported by National Key R&D Program of China (2022YFA1104804); National Natural Science Foundation of China (82472171, 32401144); Beijing Natural Science Foundation (L244089, L234021); The Innovation and Translation Fund of Peking University Third Hospital (BYSYZHKC2023106).
ABSTRACT
Pancreatic islet transplantation is a crucial treatment for managing type 1 diabetes (T1D) in clinical settings. However, the limited availability of human cadaveric islet donors and the need for ongoing administration of immunosuppressive agents post-transplantation hinder the widespread use of this treatment. Stem cell-derived islet organoids have emerged as an effective alternative to primary human islets. Nevertheless, implementing this cell replacement therapy still requires chronic immune suppression, which may result in life-long side effects. To address these challenges, innovations such as encapsulation devices, universal stem cells, and immunomodulatory strategies are being developed to mitigate immune rejection and prolong the function of the transplant. This review outlines the contemporary challenges in pancreatic β cell therapy, particularly immune rejection, and recent progress in immune-isolation devices, hypoimmunogenic stem cells, and immune regulation of transplants. A comprehensive evaluation of the advantages and limitations of these approaches will contribute to improved future clinical investigations. With these promising advancements, the application of pancreatic β cell therapy holds the potential to effectively treat T1D and benefit a larger population of T1D patients.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- 1K. Ogurtsova, L. Guariguata, N. C. Barengo, et al., “IDF Diabetes Atlas: Global Estimates of Undiagnosed Diabetes in Adults for 2021,” Diabetes Research and Clinical Practice 183 (2022): 109118, https://doi.org/10.1016/j.diabres.2021.109118.
- 2H. Sun, P. Saeedi, S. Karuranga, et al., “IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045,” Diabetes Research and Clinical Practice 183 (2022): 109119, https://doi.org/10.1016/j.diabres.2021.109119.
- 3D. Daneman, “Type 1 Diabetes,” Lancet 367, no. 9513 (2006): 847–858, https://doi.org/10.1016/s0140-6736(06)68341-4.
- 4M. A. Atkinson and N. K. Maclaren, “The Pathogenesis of Insulin-Dependent Diabetes Mellitus,” New England Journal of Medicine 331, no. 21 (1994): 1428–1436, https://doi.org/10.1056/nejm199411243312107.
- 5Y. Hayashino, S. Tsuboi, Y. Yamamoto, and H. Ishii, “Burden of Current Insulin Therapy and Expectations for Future Insulin Therapy: Results From INBEING, a Web-Based Survey in Japan,” Diabetes Therapy 15, no. 12 (2024): 2537–2555, https://doi.org/10.1007/s13300-024-01664-w.
- 6A. M. Shapiro, J. R. Lakey, E. A. Ryan, et al., “Islet Transplantation in Seven Patients With Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen,” New England Journal of Medicine 343, no. 4 (2000): 230–238, https://doi.org/10.1056/nejm200007273430401.
- 7A. M. Shapiro, M. Pokrywczynska, and C. Ricordi, “Clinical Pancreatic Islet Transplantation,” Nature Reviews Endocrinology 13, no. 5 (2017): 268–277, https://doi.org/10.1038/nrendo.2016.178.
- 8S. Dholakia, E. Royston, I. Quiroga, et al., “The Rise and Potential Fall of Pancreas Transplantation,” British Medical Bulletin 124, no. 1 (2017): 171–179, https://doi.org/10.1093/bmb/ldx039.
- 9 FDA, “ FDA Approves First Cellular Therapy to Treat Patients With Type 1 Diabetes,” https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes.
- 10H. de Kort, E. J. de Koning, T. J. Rabelink, J. A. Bruijn, and I. M. Bajema, “Islet Transplantation in Type 1 Diabetes,” BMJ 342 (2011): d217, https://doi.org/10.1136/bmj.d217.
- 11A. Citro, E. Cantarelli, and L. Piemonti, “Anti-Inflammatory Strategies to Enhance Islet Engraftment and Survival,” Current Diabetes Reports 13, no. 5 (2013): 733–744, https://doi.org/10.1007/s11892-013-0401-0.
- 12M. Tahbaz and E. Yoshihara, “Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes,” Frontiers in Endocrinology 12 (2021): 716625, https://doi.org/10.3389/fendo.2021.716625.
- 13A. Helman and D. A. Melton, “A Stem Cell Approach to Cure Type 1 Diabetes,” Cold Spring Harbor Perspectives in Biology 13, no. 1 (2021): a035741, https://doi.org/10.1101/cshperspect.a035741.
- 14B. X. Ho, A. K. K. Teo, and N. H. J. Ng, “Innovations in Bio-Engineering and Cell-Based Approaches to Address Immunological Challenges in Islet Transplantation,” Frontiers in Immunology 15 (2024): 1375177, https://doi.org/10.3389/fimmu.2024.1375177.
- 15N. J. Hogrebe, M. Ishahak, and J. R. Millman, “Developments in Stem Cell-Derived Islet Replacement Therapy for Treating Type 1 Diabetes,” Cell Stem Cell 30, no. 5 (2023): 530–548, https://doi.org/10.1016/j.stem.2023.04.002.
- 16W. F. Ballinger and P. E. Lacy, “Transplantation of Intact Pancreatic Islets in Rats,” Surgery 72, no. 2 (1972): 175–186.
- 17G. J. Kretschmer, D. R. Sutherland, A. J. Matas, W. D. Payne, and J. S. Najarian, “Autotransplantation of Pancreatic Fragments to the Portal Vein and Spleen of Totally Pancreatectomized Dogs: A Comparative Evaluation,” Annals of Surgery 187, no. 1 (1978): 79–86, https://doi.org/10.1097/00000658-197801000-00015.
- 18F. Largiadèr, E. Kolb, and U. Binswanger, “A Long-Term Functioning Human Pancreatic Islet Allotransplant,” Transplantation 29, no. 1 (1980): 76–77, https://doi.org/10.1097/00007890-198001000-00017.
- 19B. A. Marfil-Garza, S. Imes, K. Verhoeff, et al., “Pancreatic Islet Transplantation in Type 1 Diabetes: 20-Year Experience From a Single-Centre Cohort in Canada,” Lancet Diabetes and Endocrinology 10, no. 7 (2022): 519–532, https://doi.org/10.1016/s2213-8587(22)00114-0.
- 20 CITR, “Scientific Summary of the Collaborative Islet Transplant Registry (CITR), 11th Allograft Report,” 2022, https://citregistry.org/.
- 21H. Noguchi, C. Miyagi-Shiohira, K. Kurima, et al., “Islet Culture/Preservation Before Islet Transplantation,” Cell Medicine 8, no. 1–2 (2015): 25–29, https://doi.org/10.3727/215517915x689047.
- 22B. Naziruddin, S. Iwahashi, M. A. Kanak, M. Takita, T. Itoh, and M. F. Levy, “Evidence for Instant Blood-Mediated Inflammatory Reaction in Clinical Autologous Islet Transplantation,” American Journal of Transplantation 14, no. 2 (2014): 428–437, https://doi.org/10.1111/ajt.12558.
- 23J. J. Casey, J. R. Lakey, E. A. Ryan, et al., “Portal Venous Pressure Changes After Sequential Clinical Islet Transplantation,” Transplantation 74, no. 7 (2002): 913–915, https://doi.org/10.1097/00007890-200210150-00002.
- 24A. Turan, M. Tarique, L. Zhang, et al., “Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction Following Intraportal Transplantation,” Journal of Immunology 212, no. 12 (2024): 1971–1980, https://doi.org/10.4049/jimmunol.2300743.
- 25K. R. Szempruch, O. Banerjee, R. C. McCall, and C. S. Desai, “Use of Anti-Inflammatory Agents in Clinical Islet Cell Transplants: A Qualitative Systematic Analysis,” Islets 11, no. 3 (2019): 65–75, https://doi.org/10.1080/19382014.2019.1601543.
- 26J. Paez-Mayorga, J. N. Campa-Carranza, S. Capuani, et al., “Implantable Niche With Local Immunosuppression for Islet Allotransplantation Achieves Type 1 Diabetes Reversal in Rats,” Nature Communications 13, no. 1 (2022): 7951, https://doi.org/10.1038/s41467-022-35629-z.
- 27C. M. Lin and R. G. Gill, “Direct and Indirect Allograft Recognition: Pathways Dictating Graft Rejection Mechanisms,” Current Opinion in Organ Transplantation 21, no. 1 (2016): 40–44, https://doi.org/10.1097/mot.0000000000000263.
- 28J. M. Kim, S. J. Kang, S. H. Hong, et al., “Long-Term Control of Diabetes by Tofacitinib-Based Immunosuppressive Regimen After Allo Islet Transplantation in Diabetic Rhesus Monkeys That Rejected Previously Transplanted Porcine Islets,” Xenotransplantation 31, no. 2 (2024): e12850, https://doi.org/10.1111/xen.12850.
- 29X. Hu, K. White, C. Young, et al., “Hypoimmune Islets Achieve Insulin Independence After Allogeneic Transplantation in a Fully Immunocompetent Non-Human Primate,” Cell Stem Cell 31, no. 3 (2024): 334–340.e5, https://doi.org/10.1016/j.stem.2024.02.001.
- 30M. Chetboun, E. Drumez, C. Ballou, et al., “Association Between Primary Graft Function and 5-Year Outcomes of Islet Allogeneic Transplantation in Type 1 Diabetes: A Retrospective, Multicentre, Observational Cohort Study in 1210 Patients From the Collaborative Islet Transplant Registry,” Lancet Diabetes and Endocrinology 11, no. 6 (2023): 391–401, https://doi.org/10.1016/s2213-8587(23)00082-7.
- 31L. E. Becker, C. Morath, and C. Suesal, “Immune Mechanisms of Acute and Chronic Rejection,” Clinical Biochemistry 49, no. 4–5 (2016): 320–323, https://doi.org/10.1016/j.clinbiochem.2016.02.001.
- 32M. B. Roberts and J. A. Fishman, “Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the Net State of Immunosuppression,” Clinical Infectious Diseases 73, no. 7 (2021): e1302–e1317, https://doi.org/10.1093/cid/ciaa1189.
- 33J. P. Squifflet, R. W. Gruessner, and D. E. Sutherland, “The History of Pancreas Transplantation: Past, Present and Future,” Acta Chirurgica Belgica 108, no. 3 (2008): 367–378, https://doi.org/10.1080/00015458.2008.11680243.
- 34S. Reardon, “First Pig-To-Human Heart Transplant: What Can Scientists Learn?,” Nature 601, no. 7893 (2022): 305–306, https://doi.org/10.1038/d41586-022-00111-9.
- 35D. Niu, H. J. Wei, L. Lin, et al., “Inactivation of Porcine Endogenous Retrovirus in Pigs Using CRISPR-Cas9,” Science 357, no. 6357 (2017): 1303–1307, https://doi.org/10.1126/science.aan4187.
- 36N. I. Mourad, A. Perota, D. Xhema, et al., “Double Transgenic Neonatal Porcine Islets as an Alternative Source for Beta Cell Replacement Therapy,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 46 (2024): e2409138121, https://doi.org/10.1073/pnas.2409138121.
- 37A. M. J. Shapiro, D. Thompson, T. W. Donner, et al., “Insulin Expression and C-Peptide in Type 1 Diabetes Subjects Implanted With Stem Cell-Derived Pancreatic Endoderm Cells in an Encapsulation Device,” Cell Reports Medicine 2, no. 12 (2021): 100466, https://doi.org/10.1016/j.xcrm.2021.100466.
- 38A. Ramzy, D. M. Thompson, K. A. Ward-Hartstonge, et al., “Implanted Pluripotent Stem-Cell-Derived Pancreatic Endoderm Cells Secrete Glucose-Responsive C-Peptide in Patients With Type 1 Diabetes,” Cell Stem Cell 28, no. 12 (2021): 2047–2061.e5, https://doi.org/10.1016/j.stem.2021.10.003.
- 39B. Keymeulen, K. De Groot, D. Jacobs-Tulleneers-Thevissen, et al., “Encapsulated Stem Cell-Derived β Cells Exert Glucose Control in Patients With Type 1 Diabetes,” Nature Biotechnology 42, no. 10 (2024): 1507–1514, https://doi.org/10.1038/s41587-023-02055-5.
- 40T. W. Reichman, C. Ricordi, A. Naji, et al., “836-P: Glucose-Dependent Insulin Production and Insulin-Independence in Type 1 Diabetes From Stem Cell–Derived, Fully Differentiated Islet Cells—Updated Data From the VX-880 Clinical Trial,” Diabetes 72 (2023); 836-P. https://doi.org/10.2337/db23-836-P.
10.2337/db23-836-P Google Scholar
- 41 Association AD, “ Expanded FORWARD Trial Demonstrates Continued Potential for Stem Cell-Derived Islet Cell Therapy to Eliminate Need for Insulin for People With T1D,” https://www.prnewswire.com/news-releases/expanded-forward-trial-demonstrates-continued-potential-for-stem-cell-derived-islet-cell-therapy-to-eliminate-need-for-insulin-for-people-with-t1d-302178663.html.
- 42 Incorporated VP, “ Vertex Reports Third Ouarter 2024 Financial Results,” 2024, https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2024-financial-results.
- 43 Vertex, “ A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes,” https://clinicaltrials.gov/study/NCT05791201.
- 44S. Wang, Y. Du, B. Zhang, et al., “Transplantation of Chemically Induced Pluripotent Stem-Cell-Derived Islets Under Abdominal Anterior Rectus Sheath in a Type 1 Diabetes Patient,” Cell 187, no. 22 (2024): 6152–6164.e18, https://doi.org/10.1016/j.cell.2024.09.004.
- 45 NMPA, “ Approval for Human Clinical Trials,” https://www.cde.org.cn/.
- 46J. Wu, T. Li, M. Guo, et al., “Clinical Group Treating a Type 2 Diabetic Patient With Impaired Pancreatic Islet Function by Personalized Endoderm Stem Cell-Derived Islet Tissue,” Cell Discovery 10, no. 1 (2024): 45, https://doi.org/10.1038/s41421-024-00662-3.
- 47P. McClure, “ Insulin-Free Life for Diabetics Closer After Successful Cell Pouch Trial,” https://newatlas.com/health-wellbeing/cell-pouch-implant-diabetics-insulin-independent/.
- 48C. S. Sernova, “ Provides Recap of 2023 Accomplishments and Anticipated 2024 Milestones,” https://www.sernova.com/press/release/?id=388.
- 49S. C. Pino, A. J. Kruger, and R. Bortell, “The Role of Innate Immune Pathways in Type 1 Diabetes Pathogenesis,” Current Opinion in Endocrinology, Diabetes, and Obesity 17, no. 2 (2010): 126–130, https://doi.org/10.1097/MED.0b013e3283372819.
- 50T. M. Brusko, H. A. Russ, and C. L. Stabler, “Strategies for Durable β Cell Replacement in Type 1 Diabetes,” Science 373, no. 6554 (2021): 516–522, https://doi.org/10.1126/science.abh1657.
- 51D. Lim, V. Sreekanth, K. J. Cox, et al., “Engineering Designer Beta Cells With a CRISPR-Cas9 Conjugation Platform,” Nature Communications 11, no. 1 (2020): 4043, https://doi.org/10.1038/s41467-020-17725-0.
- 52C. Ricordi, J. S. Goldstein, A. N. Balamurugan, et al., “National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities,” Diabetes 65, no. 11 (2016): 3418–3428, https://doi.org/10.2337/db16-0234.
- 53P. de Vos, A. F. Hamel, and K. Tatarkiewicz, “Considerations for Successful Transplantation of Encapsulated Pancreatic Islets,” Diabetologia 45, no. 2 (2002): 159–173, https://doi.org/10.1007/s00125-001-0729-x.
- 54S. Fuchs, A. U. Ernst, L. H. Wang, et al., “Hydrogels in Emerging Technologies for Type 1 Diabetes,” Chemical Reviews 121, no. 18 (2021): 11458–11526, https://doi.org/10.1021/acs.chemrev.0c01062.
- 55Y. Zhang, J. Yu, A. R. Kahkoska, J. Wang, J. B. Buse, and Z. Gu, “Advances in Transdermal Insulin Delivery,” Advanced Drug Delivery Reviews 139 (2019): 51–70, https://doi.org/10.1016/j.addr.2018.12.006.
- 56D. Shen, H. Yu, L. Wang, et al., “Recent Progress in Design and Preparation of Glucose-Responsive Insulin Delivery Systems,” Journal of Controlled Release 321 (2020): 236–258, https://doi.org/10.1016/j.jconrel.2020.02.014.
- 57P. Fonte, F. Araújo, C. Silva, et al., “Polymer-Based Nanoparticles for Oral Insulin Delivery: Revisited Approaches,” Biotechnology Advances 33, no. 6 (2015): 1342–1354, https://doi.org/10.1016/j.biotechadv.2015.02.010.
- 58J. Wang, Z. Wang, J. Yu, A. R. Kahkoska, J. B. Buse, and Z. Gu, “Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation,” Advanced Materials 32, no. 13 (2020): e1902004, https://doi.org/10.1002/adma.201902004.
- 59M. Farina, J. F. Alexander, U. Thekkedath, M. Ferrari, and A. Grattoni, “Cell Encapsulation: Overcoming Barriers in Cell Transplantation in Diabetes and Beyond,” Advanced Drug Delivery Reviews 139 (2019): 92–115, https://doi.org/10.1016/j.addr.2018.04.018.
- 60S. M. Kang, J. H. Lee, Y. S. Huh, and S. Takayama, “Alginate Microencapsulation for Three-Dimensional in Vitro Cell Culture,” ACS Biomaterials Science & Engineering 7, no. 7 (2021): 2864–2879, https://doi.org/10.1021/acsbiomaterials.0c00457.
- 61K. Ajima, N. Tsuda, T. Takaki, et al., “A Porcine Islet-Encapsulation Device That Enables Long-Term Discordant Xenotransplantation in Immunocompetent Diabetic Mice, Cell Rep” Methods 3, no. 1 (2023): 100370, https://doi.org/10.1016/j.crmeth.2022.100370.
- 62M. A. Bochenek, O. Veiseh, A. J. Vegas, et al., “Alginate Encapsulation as Long-Term Immune Protection of Allogeneic Pancreatic Islet Cells Transplanted Into the Omental Bursa of Macaques,” Nature Biomedical Engineering 2, no. 11 (2018): 810–821, https://doi.org/10.1038/s41551-018-0275-1.
- 63S. Matsumoto, A. Abalovich, C. Wechsler, S. Wynyard, and R. B. Elliott, “Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes,” eBioMedicine 12 (2016): 255–262, https://doi.org/10.1016/j.ebiom.2016.08.034.
- 64R. M. Olabisi, “Cell Microencapsulation With Synthetic Polymers,” Journal of Biomedical Materials Research. Part A 103, no. 2 (2015): 846–859, https://doi.org/10.1002/jbm.a.35205.
- 65Y. Zhang, D. An, Y. Pardo, et al., “High-Water-Content and Resilient PEG-Containing Hydrogels With Low Fibrotic Response,” Acta Biomaterialia 53 (2017): 100–108, https://doi.org/10.1016/j.actbio.2017.02.028.
- 66D. W. Branch, B. C. Wheeler, G. J. Brewer, and D. E. Leckband, “Long-Term Stability of Grafted Polyethylene Glycol Surfaces for Use With Microstamped Substrates in Neuronal Cell Culture,” Biomaterials 22, no. 10 (2001): 1035–1047, https://doi.org/10.1016/s0142-9612(00)00343-4.
- 67K. C. Yang, Z. Qi, C. C. Wu, et al., “The Cytoprotection of Chitosan Based Hydrogels in Xenogeneic Islet Transplantation: An In Vivo Study in Streptozotocin-Induced Diabetic Mouse,” Biochemical and Biophysical Research Communications 393, no. 4 (2010): 818–823, https://doi.org/10.1016/j.bbrc.2010.02.089.
- 68H. K. Yang, D. S. Ham, H. S. Park, et al., “Long-Term Efficacy and Biocompatibility of Encapsulated Islet Transplantation With Chitosan-Coated Alginate Capsules in Mice and Canine Models of Diabetes,” Transplantation 100, no. 2 (2016): 334–343, https://doi.org/10.1097/tp.0000000000000927.
- 69G. Basta, P. Montanucci, G. Luca, et al., “Long-Term Metabolic and Immunological Follow-Up of Nonimmunosuppressed Patients With Type 1 Diabetes Treated With Microencapsulated Islet Allografts: Four Cases,” Diabetes Care 34, no. 11 (2011): 2406–2409, https://doi.org/10.2337/dc11-0731.
- 70D. A. Alagpulinsa, J. J. L. Cao, R. K. Driscoll, et al., “Alginate-Microencapsulation of Human Stem Cell-Derived β Cells With CXCL12 Prolongs Their Survival and Function in Immunocompetent Mice Without Systemic Immunosuppression,” American Journal of Transplantation 19, no. 7 (2019): 1930–1940, https://doi.org/10.1111/ajt.15308.
- 71W. Liu, J. A. Flanders, L. H. Wang, et al., “A Safe, Fibrosis-Mitigating, and Scalable Encapsulation Device Supports Long-Term Function of Insulin-Producing Cells,” Small 18, no. 8 (2022): e2104899, https://doi.org/10.1002/smll.202104899.
- 72T. Kobayashi, Y. Aomatsu, H. Iwata, et al., “Indefinite Islet Protection From Autoimmune Destruction in Nonobese Diabetic Mice by Agarose Microencapsulation Without Immunosuppression,” Transplantation 75, no. 5 (2003): 619–625, https://doi.org/10.1097/01.Tp.0000053749.36365.7e.
- 73T. Knobeloch, S. E. M. Abadi, J. Bruns, S. P. Zustiak, and G. Kwon, “Injectable Polyethylene Glycol Hydrogel for Islet Encapsulation: An In Vitro and In Vivo Characterization,” Biomedical Physics & Engineering Express 3 (2017): 035022, https://doi.org/10.1088/2057-1976/aa742b.
- 74Q. Liu, A. Chiu, L. Wang, et al., “Developing Mechanically Robust, Triazole-Zwitterionic Hydrogels to Mitigate Foreign Body Response (FBR) for Islet Encapsulation,” Biomaterials 230 (2020): 119640, https://doi.org/10.1016/j.biomaterials.2019.119640.
- 75M. Qi, Y. Gu, N. Sakata, et al., “PVA Hydrogel Sheet Macroencapsulation for the Bioartificial Pancreas,” Biomaterials 25, no. 27 (2004): 5885–5892, https://doi.org/10.1016/j.biomaterials.2004.01.050.
- 76Q. Wang, Y. X. Huang, L. Liu, et al., “Pancreatic Islet Transplantation: Current Advances and Challenges,” Frontiers in Immunology 15 (2024): 1391504, https://doi.org/10.3389/fimmu.2024.1391504.
- 77X. Wang, K. G. Maxwell, K. Wang, et al., “A Nanofibrous Encapsulation Device for Safe Delivery of Insulin-Producing Cells to Treat Type 1 Diabetes,” Science Translational Medicine 13, no. 596 (2021): eabb4601, https://doi.org/10.1126/scitranslmed.abb4601.
- 78Q. Liu, X. Wang, A. Chiu, et al., “A Zwitterionic Polyurethane Nanoporous Device With Low Foreign-Body Response for Islet Encapsulation,” Advanced Materials 33, no. 39 (2021): e2102852, https://doi.org/10.1002/adma.202102852.
- 79E. Dolgin, “Diabetes: Encapsulating the Problem,” Nature 540, no. 7632 (2016): S60–s62, https://doi.org/10.1038/540S60a.
- 80R. A. Valdés-González, L. M. Dorantes, G. N. Garibay, et al., “Xenotransplantation of Porcine Neonatal Islets of Langerhans and Sertoli Cells: A 4-Year Study,” European Journal of Endocrinology 153, no. 3 (2005): 419–427, https://doi.org/10.1530/eje.1.01982.
- 81T. Boettler, D. Schneider, Y. Cheng, et al., “Pancreatic Tissue Transplanted in TheraCyte Encapsulation Devices Is Protected and Prevents Hyperglycemia in a Mouse Model of Immune-Mediated Diabetes,” Cell Transplantation 25, no. 3 (2016): 609–614, https://doi.org/10.3727/096368915x688939.
- 82P. O. Carlsson, D. Espes, A. Sedigh, et al., “Transplantation of Macroencapsulated Human Islets Within the Bioartificial Pancreas βAir to Patients With Type 1 Diabetes Mellitus,” American Journal of Transplantation 18, no. 7 (2018): 1735–1744, https://doi.org/10.1111/ajt.14642.
- 83L. H. Wang, A. U. Ernst, D. An, et al., “A Bioinspired Scaffold for Rapid Oxygenation of Cell Encapsulation Systems,” Nature Communications 12, no. 1 (2021): 5846, https://doi.org/10.1038/s41467-021-26126-w.
- 84H. RR, J. Pettus, J. Wilensky, et al., “Initial Clinical Evaluation of VC-01TM Combination Product—A Stem Cell–Derived Islet Replacement for Type 1 Diabetes (T1D),” Diabetes 67, no. 1 (2018): 138-OR, https://doi.org/10.2337/db18-138-OR.
10.2337/db18?138?OR Google Scholar
- 85 Vertex, “ Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes,” https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug.
- 86L. H. Wang, A. U. Ernst, J. A. Flanders, et al., “An Inverse-Breathing Encapsulation System for Cell Delivery,” Science Advances 7, no. 20 (2021): eabd5835, https://doi.org/10.1126/sciadv.abd5835.
- 87D. An, A. Chiu, J. A. Flanders, et al., “Designing a Retrievable and Scalable Cell Encapsulation Device for Potential Treatment of Type 1 Diabetes,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 2 (2018): E263–e272, https://doi.org/10.1073/pnas.1708806115.
- 88P. W. Reichman, J. Markmann, J. Fung, et al., “ Improvement in Glycaemic Control and Elimination of Exogenous Insulin Use in Patients With Type 1 Diabetes Infused With Fully Differentiated Islet Cells (VX-880),” https://cattendee.abstractsonline.com/meeting/20620/presentation/2943.
- 89L. H. Wang, B. A. Marfil-Garza, A. U. Ernst, et al., “Inflammation-Induced Subcutaneous Neovascularization for the Long-Term Survival of Encapsulated Islets Without Immunosuppression,” Nature Biomedical Engineering 8, no. 10 (2024): 1266–1284, https://doi.org/10.1038/s41551-023-01145-8.
- 90Q. Ye, T. C. Sung, J. M. Yang, Q. D. Ling, Y. He, and A. Higuchi, “Generation of Universal and Hypoimmunogenic Human Pluripotent Stem Cells,” Cell Proliferation 53, no. 12 (2020): e12946, https://doi.org/10.1111/cpr.12946.
- 91“Complete Sequence and Gene Map of a Human Major Histocompatibility Complex. The MHC Sequencing Consortium,” Nature 401, no. 6756 (1999): 921–923, https://doi.org/10.1038/44853.
- 92H. Heinrichs and H. T. Orr, “HLA Non-A,B,C Class I Genes: Their Structure and Expression,” Immunologic Research 9, no. 4 (1990): 265–274, https://doi.org/10.1007/bf02935526.
- 93S. D. Sackett, S. J. Kaplan, S. A. Mitchell, et al., “Genetic Engineering of Immune Evasive Stem Cell-Derived Islets,” Transplant International 35 (2022): 10817, https://doi.org/10.3389/ti.2022.10817.
- 94N. Rouas-Freiss, R. M. Gonçalves, C. Menier, J. Dausset, and E. D. Carosella, “Direct Evidence to Support the Role of HLA-G in Protecting the Fetus From Maternal Uterine Natural Killer Cytolysis,” Proceedings of the National Academy of Sciences of the United States of America 94, no. 21 (1997): 11520–11525, https://doi.org/10.1073/pnas.94.21.11520.
- 95N. Lila, A. Carpentier, C. Amrein, I. Khalil-Daher, J. Dausset, and E. D. Carosella, “Implication of HLA-G Molecule in Heart-Graft Acceptance,” Lancet 355, no. 9221 (2000): 2138, https://doi.org/10.1016/s0140-6736(00)02386-2.
- 96H. Xu, B. Wang, M. Ono, et al., “Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs With Enhanced Immune Compatibility,” Cell Stem Cell 24, no. 4 (2019): 566–578.e7, https://doi.org/10.1016/j.stem.2019.02.005.
- 97P. Wang, M. V. Yigit, C. Ran, et al., “A Theranostic Small Interfering RNA Nanoprobe Protects Pancreatic Islet Grafts From Adoptively Transferred Immune Rejection,” Diabetes 61, no. 12 (2012): 3247–3254, https://doi.org/10.2337/db12-0441.
- 98C. H. Hong, H. J. Sohn, H. J. Lee, H. I. Cho, and T. G. Kim, “Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System,” Journal of Immunotherapy 40, no. 6 (2017): 201–210, https://doi.org/10.1097/cji.0000000000000176.
- 99D. Wang, Y. Quan, Q. Yan, J. E. Morales, and R. A. Wetsel, “Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells,” Stem Cells Translational Medicine 4, no. 10 (2015): 1234–1245, https://doi.org/10.5966/sctm.2015-0049.
- 100E. Sintov, I. Nikolskiy, V. Barrera, et al., “Whole-Genome CRISPR Screening Identifies Genetic Manipulations to Reduce Immune Rejection of Stem Cell-Derived Islets,” Stem Cell Reports 17, no. 9 (2022): 1976–1990, https://doi.org/10.1016/j.stemcr.2022.08.002.
- 101F. Rieux-Laucat, F. Le Deist, C. Hivroz, et al., “Mutations in Fas Associated With Human Lymphoproliferative Syndrome and Autoimmunity,” Science 268, no. 5215 (1995): 1347–1349, https://doi.org/10.1126/science.7539157.
- 102K. B. Woodward, H. Zhao, P. Shrestha, et al., “Pancreatic Islets Engineered With a FasL Protein Induce Systemic Tolerance at the Induction Phase That Evolves Into Long-Term Graft-Localized Immune Privilege,” American Journal of Transplantation 20, no. 5 (2020): 1285–1295, https://doi.org/10.1111/ajt.15747.
- 103S. Jaiswal, C. H. Jamieson, W. W. Pang, et al., “CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis,” Cell 138, no. 2 (2009): 271–285, https://doi.org/10.1016/j.cell.2009.05.046.
- 104T. Deuse, X. Hu, A. Gravina, et al., “Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients,” Nature Biotechnology 37, no. 3 (2019): 252–258, https://doi.org/10.1038/s41587-019-0016-3.
- 105E. Yoshihara, C. O'Connor, E. Gasser, et al., “Immune-evasive human islet-like organoids ameliorate diabetes,” Nature 586, no. 7830 (2020): 606–611, https://doi.org/10.1038/s41586-020-2631-z.
- 106D. Gerace, Q. Zhou, J. H. Kenty, et al., “Engineering Human Stem Cell-Derived Islets to Evade Immune Rejection and Promote Localized Immune Tolerance,” Cell Reports Medicine 4, no. 1 (2023): 100879, https://doi.org/10.1016/j.xcrm.2022.100879.
- 107J. Harding, K. Vintersten-Nagy, H. Yang, et al., “Immune-Privileged Tissues Formed From Immunologically Cloaked Mouse Embryonic Stem Cells Survive Long Term in Allogeneic Hosts, Nature” Biomedical Engineering 8, no. 4 (2024): 427–442, https://doi.org/10.1038/s41551-023-01133-y.
- 108A. R. Pepper, A. Bruni, and A. M. J. Shapiro, “Clinical Islet Transplantation: Is the Future Finally Now?,” Current Opinion in Organ Transplantation 23, no. 4 (2018): 428–439, https://doi.org/10.1097/mot.0000000000000546.
- 109D. M. Headen, K. B. Woodward, M. M. Coronel, et al., “Local Immunomodulation Fas Ligand-Engineered Biomaterials Achieves Allogeneic Islet Graft Acceptance,” Nature Materials 17, no. 8 (2018): 732–739, https://doi.org/10.1038/s41563-018-0099-0.
- 110M. Skoumal, K. B. Woodward, H. Zhao, et al., “Localized Immune Tolerance From FasL-Functionalized PLG Scaffolds,” Biomaterials 192 (2019): 271–281, https://doi.org/10.1016/j.biomaterials.2018.11.015.
- 111M. M. Coronel, K. E. Martin, M. D. Hunckler, et al., “Immunotherapy via PD-L1-Presenting Biomaterials Leads to Long-Term Islet Graft Survival,” Science Advances 6, no. 35 (2020): eaba5573, https://doi.org/10.1126/sciadv.aba5573.
- 112M. M. Coronel, S. W. Linderman, K. E. Martin, et al., “Delayed Graft Rejection in Autoimmune Islet Transplantation via Biomaterial Immunotherapy,” American Journal of Transplantation 23, no. 11 (2023): 1709–1722, https://doi.org/10.1016/j.ajt.2023.07.023.
- 113J. Lei, M. M. Coronel, E. S. Yolcu, et al., “FasL Microgels Induce Immune Acceptance of Islet Allografts in Nonhuman Primates,” Science Advances 8, no. 19 (2022): eabm9881, https://doi.org/10.1126/sciadv.abm9881.
- 114A. Grattoni, G. Korbutt, A. A. Tomei, et al., “Harnessing Cellular Therapeutics for Type 1 Diabetes Mellitus: Progress, Challenges, and the Road Ahead, Nature Reviews” Endocrinology 21 (2024): 14–30, https://doi.org/10.1038/s41574-024-01029-0.
- 115X. Wang, N. K. Brown, B. Wang, et al., “Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells,” Advanced Science 8, no. 17 (2021): e2003708, https://doi.org/10.1002/advs.202003708.
- 116A. Scuteri, E. Donzelli, V. Rodriguez-Menendez, et al., “A Double Mechanism for the Mesenchymal Stem Cells' Positive Effect on Pancreatic Islets,” PLoS One 9, no. 1 (2014): e84309, https://doi.org/10.1371/journal.pone.0084309.
- 117P. Kabakchieva, Y. Assyov, S. Gerasoudis, et al., “Islet Transplantation-Immunological Challenges and Current Perspectives,” World Journal of Transplantation 13, no. 4 (2023): 107–121, https://doi.org/10.5500/wjt.v13.i4.107.
- 118F. R. Li, X. G. Wang, C. Y. Deng, H. Qi, L. L. Ren, and H. X. Zhou, “Immune Modulation of Co-Transplantation Mesenchymal Stem Cells With Islet on T and Dendritic Cells,” Clinical and Experimental Immunology 161, no. 2 (2010): 357–363, https://doi.org/10.1111/j.1365-2249.2010.04178.x.
- 119X. Wang, K. Wang, M. Yu, et al., “Engineered Immunomodulatory Accessory Cells Improve Experimental Allogeneic Islet Transplantation Without Immunosuppression,” Science Advances 8, no. 29 (2022): eabn0071, https://doi.org/10.1126/sciadv.abn0071.
- 120C. Raffin, L. T. Vo, and J. A. Bluestone, “T(Reg) Cell-Based Therapies: Challenges and Perspectives,” Nature Reviews Immunology 20, no. 3 (2020): 158–172, https://doi.org/10.1038/s41577-019-0232-6.
- 121X. Luo, K. V. Tarbell, H. Yang, et al., “Dendritic Cells With TGF-beta1 Differentiate Naive CD4+CD25- T Cells Into Islet-Protective Foxp3+ Regulatory T Cells,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 8 (2007): 2821–2826, https://doi.org/10.1073/pnas.0611646104.
- 122J. G. Graham, X. Zhang, A. Goodman, et al., “PLG Scaffold Delivered Antigen-Specific Regulatory T Cells Induce Systemic Tolerance in Autoimmune Diabetes,” Tissue Engineering. Part A 19, no. 11–12 (2013): 1465–1475, https://doi.org/10.1089/ten.TEA.2012.0643.
- 123M. Zieliński, M. Żalińska, D. Iwaszkiewicz-Grześ, et al., “Combined Therapy With CD4(+) CD25highCD127(−) T Regulatory Cells and Anti-CD20 Antibody in Recent-Onset Type 1 Diabetes Is Superior to Monotherapy: Randomized Phase I/II Trial,” Diabetes, Obesity & Metabolism 24, no. 8 (2022): 1534–1543, https://doi.org/10.1111/dom.14723.
- 124G. Sun, J. Shan, Y. Li, et al., “Adoptive Infusion of Tolerogenic Dendritic Cells Prolongs the Survival of Pancreatic Islet Allografts: A Systematic Review of 13 Mouse and Rat Studies,” PLoS One 7, no. 12 (2012): e52096, https://doi.org/10.1371/journal.pone.0052096.
- 125C. Obregon, R. Kumar, M. A. Pascual, G. Vassalli, and D. Golshayan, “Update on Dendritic Cell-Induced Immunological and Clinical Tolerance,” Frontiers in Immunology 8 (2017): 1514, https://doi.org/10.3389/fimmu.2017.01514.
- 126Y. Huang, P. Chen, C. B. Zhang, et al., “Kidney-Derived Mesenchymal Stromal Cells Modulate Dendritic Cell Function to Suppress Alloimmune Responses and Delay Allograft Rejection,” Transplantation 90, no. 12 (2010): 1307–1311, https://doi.org/10.1097/TP.0b013e3181fdd9eb.
- 127J. Bart, H. J. Groen, W. T. van der Graaf, et al., “An Oncological View on the Blood-Testis Barrier,” Lancet Oncology 3, no. 6 (2002): 357–363, https://doi.org/10.1016/s1470-2045(02)00776-3.
- 128G. S. Korbutt, J. F. Elliott, and R. V. Rajotte, “Cotransplantation of Allogeneic Islets With Allogeneic Testicular Cell Aggregates Allows Long-Term Graft Survival Without Systemic Immunosuppression,” Diabetes 46, no. 2 (1997): 317–322, https://doi.org/10.2337/diab.46.2.317.
- 129P. Lan, W. Zhan, J. Wang, L. Yan, L. Xiao, and X. Wu, “Immune Privilege Induced by Cotransplantation of Islet and Allogeneic Testicular Cells,” Chinese Medical Journal 114, no. 10 (2001): 1026–1029.
- 130W. Suarez-Pinzon, G. S. Korbutt, R. Power, J. Hooton, R. V. Rajotte, and A. Rabinovitch, “Testicular Sertoli Cells Protect Islet Beta-Cells From Autoimmune Destruction in NOD Mice by a Transforming Growth Factor-beta1-Dependent Mechanism,” Diabetes 49, no. 11 (2000): 1810–1818, https://doi.org/10.2337/diabetes.49.11.1810.
- 131Z. Yin, D. Chen, F. Hu, et al., “Cotransplantation With Xenogenetic Neonatal Porcine Sertoli Cells Significantly Prolongs Islet Allograft Survival in Nonimmunosuppressive Rats,” Transplantation 88, no. 3 (2009): 339–345, https://doi.org/10.1097/TP.0b013e3181ae5dcf.
- 132J. Liang, N. Wang, J. He, et al., “Induction of Sertoli-Like Cells From Human Fibroblasts by NR5A1 and GATA4,” eLife 8 (2019): e48767, https://doi.org/10.7554/eLife.48767.
- 133H. S. Park, E. Y. Lee, Y. H. You, et al., “Long-Term Efficacy of Encapsulated Xenogeneic Islet Transplantation: Impact of Encapsulation Techniques and Donor Genetic Traits,” Journal of Diabetes Investigation 15, no. 6 (2024): 693–703, https://doi.org/10.1111/jdi.14216.
- 134A. C. Farney, D. E. Sutherland, and E. C. Opara, “Evolution of Islet Transplantation for the Last 30 Years,” Pancreas 45, no. 1 (2016): 8–20, https://doi.org/10.1097/mpa.0000000000000391.
- 135J. D. Kepple, J. M. Barra, M. E. Young, C. S. Hunter, and H. M. Tse, “Islet Transplantation Into Brown Adipose Tissue Can Delay Immune Rejection,” JCI Insight 7, no. 4 (2022): e152800, https://doi.org/10.1172/jci.insight.152800.
- 136A. Sun, H. Hayat, E. Kenyon, et al., “Brown Adipose Tissue as a Unique Niche for Islet Organoid Transplantation: Insights From in Vivo Imaging,” Transplantation Direct 10, no. 7 (2024): e1658, https://doi.org/10.1097/txd.0000000000001658.
Citing Literature
